{"filing":{"accession_number":"0001213900-26-084687","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-31","primary_document":"ea0300286-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026084687/ea0300286-8k_jasper.htm"},"events":[{"id":23190,"run_id":20986,"accession_number":"0001213900-26-084687","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This 8-K Item 5.07 discloses the results of Jasper Therapeutics' 2026 Annual Meeting of Stockholders held on July 31, 2026, including voting outcomes for four proposals: election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the standard disclosure required under Item 5.07 for shareholder meeting results.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23357,"accession_number":"0001213900-26-084687","item_number":"5.07","item_title":"Submission of","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Jasper Therapeutics' 2026 Annual Meeting of Stockholders held on July 31, 2026, including voting outcomes for four proposals: election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the standard disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:43:37.696602+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23357,"accession_number":"0001213900-26-084687","item_number":"5.07","item_title":"Submission of","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Jasper Therapeutics' 2026 Annual Meeting of Stockholders held on July 31, 2026, including voting outcomes for four proposals: election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the standard disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:43:37.696602+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-08-03"}]}